| Literature DB >> 30324351 |
André Mansinho1, Daniela Macedo1, Isabel Fernandes2,3, Luís Costa4,5.
Abstract
Prostate cancer is the most common malignancy in men, and remains the second leading cause of cancer-related death in this gender [1]. Data suggests that 10-20% of patients with prostate cancer metastasis develop castration-resistant prostate cancer (CRPC) within 5 years of follow-up, and that the median survival since development of castration resistance is approximately 14 months (range 9-30) [2]. Additionally, patients with non-metastatic CRPC are at higher risk of disease progression. Approximately 15-33% of patients develop metastasis within 2 years, increasing the mortality burden in this population [3, 4].Entities:
Mesh：
Year: 2018 PMID： 30324351 DOI： 10.1007/978-3-319-99286-0_7
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622